Brain Neurotherapy Bio, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.brainneubio.com
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
GDNF Gene Therapy for Multiple System Atrophy
- Conditions
- Multiple System Atrophy
- Interventions
- Biological: AAV2-GDNF gene therapyProcedure: Sham (Placebo) Surgery
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Brain Neurotherapy Bio, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04680065
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
GDNF Gene Therapy for Parkinson's Disease
- Conditions
- Parkinson's Disease
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Brain Neurotherapy Bio, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04167540
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸The Ohio State University Medical Center, Columbus, Ohio, United States
News
Multiple System Atrophy Pipeline Shows Promise with 22+ Therapies in Development as FDA Grants Fast Track Designations
The global Multiple System Atrophy (MSA) market is experiencing significant growth driven by emerging alpha-synuclein targeting therapies and advanced diagnostic technologies including high-resolution MRI and biomarker identification.